Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the first quarter ended March 31, 2013. Revenue and other income for the first quarter of 2013 was approximately $374,000, including $132,000 in sales of LuViva® devices...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its first quarter ended March 31,...
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) today announced that multi-center, clinical trial results for the LuViva® Advanced Cervical Scan are set to be published in an upcoming issue of Gynecologic Oncology, the official publication of the Society of...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it shipped its first Edition 3 CE marked LuViva® Advanced Cervical Scan unit to its distributor in Turkey. The delivery is the first of 15 to 20 units expected to be shipped to distributors in...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the fourth quarter and year ended December 31, 2012. Revenue for the fourth quarter of 2012 was approximately $1.0 million, compared to approximately $896,000 in the fourth...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter and year ended...
